End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
10.44 CNY | -0.67% | -3.78% | -2.70% |
Apr. 25 | Zhejiang Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
2023 | Zhejiang Medicine Wins Nod to Trial Digestive Acid Drug | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The company appears to be poorly valued given its net asset value.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.70% | 1.38B | C+ | ||
+37.74% | 723B | C+ | ||
+34.64% | 595B | B | ||
-2.07% | 369B | C+ | ||
+20.25% | 332B | B- | ||
+2.99% | 282B | C+ | ||
+16.96% | 244B | B+ | ||
+9.72% | 208B | B- | ||
-4.46% | 205B | A+ | ||
+7.43% | 166B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600216 Stock
- Ratings Zhejiang Medicine Co., Ltd.